• Aucun résultat trouvé

Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism

N/A
N/A
Protected

Academic year: 2022

Partager "Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism"

Copied!
63
0
0

Texte intégral

(1)

Article

Reference

Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism

PATEL, Parth, et al.

Abstract

Pulmonary embolism (PE) is a common, potentially life-threatening yet treatable condition.

Prompt diagnosis and expeditious therapeutic intervention is of paramount importance for optimal patient management. Our objective was to systematically review the accuracy of D-dimer assay, compression ultrasonography (CUS), computed tomography pulmonary angiography (CTPA), and ventilation-perfusion (V/Q) scanning for the diagnosis of suspected first and recurrent PE. We searched Cochrane Central, MEDLINE, and EMBASE for eligible studies, reference lists of relevant reviews, registered trials, and relevant conference proceedings. 2 investigators screened and abstracted data. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 and certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation framework. We pooled estimates of sensitivity and specificity. The review included 61 studies. The pooled estimates for D-dimer sensitivity and specificity were 0.97 (95% confidence interval [CI], 0.96-0.98) and 0.41 (95% CI, 0.36-0.46) respectively, whereas CTPA sensitivity and [...]

PATEL, Parth, et al. Systematic review and meta-analysis of test accuracy for the diagnosis of suspected pulmonary embolism. Blood advances, 2020, vol. 4, no. 18, p. 4296-4311

DOI : 10.1182/bloodadvances.2019001052 PMID : 32915980

Available at:

http://archive-ouverte.unige.ch/unige:155633

Disclaimer: layout of this document may differ from the published version.

1 / 1

(2)

American Society of Hematology Guidelines for Management of Venous Thromboembolism: Diagnosis of Venous Thromboembolism

Supplementary Material 1. Search Strategies Recommendations 1-10: Diagnosis of Venous Thromboembolism

OVERVIEW

Interface: Ovid

Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present

Date of Search: May 9th, 2016

Study Types: Systematic reviews; diagnostic test accuracy studies; randomized trials

Limits: None

Search Strategy: search terms (number of results) Any diagnostic intervention (CTPA, CUS, D-dimer, VQ):

1 ultrasonography/ or ultrasonography, doppler/ (77097) 2 (ultrasound$ or ultrason$ or sonograph$).mp. (365834) 3 or/1-2 (365834)

4 Fibrin Fibrinogen Degradation Products/ (7338) 5 (D-dimer or d dimer).mp. (7096)

6 (label$ adj2 (fibrogen or fibrinogen)).mp. (631) 7 4 or 5 or 6 (11390)

8 exp Cone-Beam Computed Tomography/ (5051) 9 Tomography, Spiral Computed/ (6878)

10 Tomography, X-Ray Computed/ (317079)

11 (compute* tomograph* or compute*-tomograph*).mp. (222821) 12 or/8-11 (431702)

13 exp Ventilation-Perfusion Ratio/ (5575)

14 (lung adj1 (ventilation or perfusion)).ti,ab,kw. (5817) 15 (lung adj ventilation adj scan).ti,ab,kw. (1)

16 (lung adj perfusion adj scan).ti,ab,kw. (146) 17 (lung adj1 scan).ti,ab,kw. (1081)

18 VQ scan.mp. (25)

19 13 or 14 or 15 or 16 or 17 or 18 (11400) 20 3 or 7 or 12 or 19 (773789)

VTE terms:

21 exp Thromboembolism/ or exp Venous Thromboembolism/ (47568) 22 exp Pulmonary Embolism/ (33893)

23 exp Venous Thrombosis/ (48320) 24 Thrombophlebitis/ (21375) 25 (DVT or VTE or PE).mp. (39840)

26 ((Pulmon$ or vein or venous or lung) adj (Emboli$ or thromb$)).mp. (92654)

27 (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*).mp. (326912) 28 (((deep or thromb* or stasis) adj2 (vein* or venous)) or (blood flow stasis or blood clot)).mp. (67667) 29 or/21-28 (368661)

Diagnosis filter:

30 exp "Sensitivity and Specificity"/ (469183) 31 (sensitivity or specificity).tw. (809446) 32 (predictive adj3 value$).tw. (81055)

(3)

American Society of Hematology Guidelines for Management of Venous Thromboembolism: Diagnosis of Venous Thromboembolism

33 exp diagnostic errors/ (101771)

34 ((false adj positiv$) or (false adj negativ$)).tw. (62229) 35 (observer adj variation$).tw. (1026)

36 (roc adj curve$).tw. (18740) 37 (likelihood adj3 ratio$).tw. (11054) 38 likelihood functions/ (18752)

39 *Thromboembolism/di, ra, ri, us (798) 40 *Thrombophlebitis/di, ra, ri, us (3026) 41 *Venous Thrombosis/di, ra, ri, us (3030) 42 or/30-41 (1283612)

43 20 and 29 and 42 (8812) Annotation: Any diagnostic intervention AND VTE AND Diagnosis filter Systematic review filter:

44 meta-analysis/ (65208) 45 meta-analysis as topic/ (14831)

46 (meta analy* or metanaly* or metaanaly*).ti,ab. (90932)

47 (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab. (30721) 48 ((systematic* or evidence*) adj2 (review* or overview*)).ti,ab. (105255)

49 (search strategy or search criteria or systematic search or study selection or data extraction).ab. (33398) 50 (search* adj4 literature).ab. (37180)

51 (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. (119376)

52 ((pool* or combined) adj2 (data or trials or studies or results)).ab. (38566) 53 cochrane.jw. (12302)

54 or/44-53 (287349)

55 animals/ not humans/ (4203767) 56 exp Animals, Laboratory/ (770845) 57 exp Animal Experimentation/ (7910) 58 exp Models, Animal/ (464566) 59 exp Rodentia/ (2869455)

60 (rat or rats or mouse or mice).ti. (1189636) 61 or/55-60 (4963714)

62 54 not 61 (274387) 63 43 and 62 (254) 64 43 not 63 (8558) Records Retrieved:

Systematic review = 254 Other study design = 8558

(4)

American Society of Hematology Guidelines for Management of Venous Thromboembolism: Diagnosis of Venous Thromboembolism

OVERVIEW

Interface: Ovid

Database: Embase 1974 to 2016 Week 07 Date of Search: May 9th, 2016

Study Types: Systematic reviews; diagnostic test accuracy studies; randomized trials

Limits: None

Search Strategy: search terms (number of results) Any diagnostic intervention (CTPA, CUS, D-dimer, VQ):

1 ultrasonography/ or ultrasonography, doppler/ (195494) 2 (ultrasound$ or ultrason$ or sonograph$).mp. (479288) 3 1 or 2 (554916)

4 fibrin degradation product/ (3142) 5 D dimer/ (13156)

6 (D-dimer or d dimer).mp. (16014)

7 (label$ adj2 (fibrogen or fibrinogen)).mp. (557) 8 4 or 5 or 6 or 7 (18440)

9 exp cone beam computed tomography/ (8539) 10 spiral computer assisted tomography/ (10925) 11 computer assisted tomography/ (580883)

12 (compute* tomograph* or compute*-tomograph*).mp. (360312) 13 or/9-12 (744247)

14 exp lung scintiscanning/ (6764) 15 exp Ventilation-Perfusion Ratio/ (6101)

16 (lung adj1 (ventilation or perfusion)).ti,ab,kw. (7981) 17 (lung adj ventilation adj scan).ti,ab,kw. (3)

18 (lung adj perfusion adj scan).ti,ab,kw. (218) 19 (lung adj1 scan).ti,ab,kw. (1348)

20 VQ scan.mp. (105)

21 14 or 15 or 16 or 17 or 18 or 19 or 20 (18644)

22 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 (1239511)

VTE terms:

23 exp vein thrombosis/ (100825)

24 exp Venous Thromboembolism/ (111295) 25 exp 'lung embolism'/ (70029)

26 Thrombophlebitis/ (16025) 27 (PE or DVT or VTE).mp. (62340)

28 ((Pulmon$ or vein or venous or lung) adj (Emboli$ or thromb$)).mp. (166579)

29 (thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*).mp. (527773) 30 (((deep or thromb* or stasis) adj2 (vein* or venous)) or (blood flow stasis or blood clot)).mp. (158324) 31 or/23-30 (597688)

Diagnosis filter:

32 exp "sensitivity and specificity"/ (245520) 33 (sensitivity or specificity).tw. (958912) 34 (predictive adj3 value$).tw. (114518)

35 ((false adj positiv$) or (false adj negativ$)).tw. (77829)

(5)

American Society of Hematology Guidelines for Management of Venous Thromboembolism: Diagnosis of Venous Thromboembolism

36 (observer adj variation$).tw. (1345) 37 (roc adj curve$).tw. (33158) 38 (likelihood adj3 ratio$).tw. (14400) 39 *Diagnostic Accuracy/ (6352) 40 *Thromboembolism/di (2018) 41 *Thrombophlebitis/di (1624) 42 *Venous Thrombosis/di (926)

43 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 (1192770)

44 22 and 31 and 43 (8959) Annotation: Any diagnostic intervention AND VTE AND Diagnosis filter Systematic review filter:

45 systematic review/ (105938) 46 meta-analysis/ (108354)

47 (meta analy* or metanaly* or metaanaly*).ti,ab. (119945)

48 (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab. (35710) 49 ((systematic* or evidence*) adj2 (review* or overview*)).ti,ab. (129874)

50 (search strategy or search criteria or systematic search or study selection or data extraction).ab. (38947) 51 (search* adj4 literature).ab. (46763)

52 (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. (147674)

53 ((pool* or combined) adj2 (data or trials or studies or results)).ab. (49701) 54 cochrane.jw. (13184)

55 or/45-54 (384419)

56 animals/ not humans/ (1150971) 57 nonhuman/ (4742930)

58 exp Animal Experiment/ (1824805) 59 exp Experimental Animal/ (508398) 60 animal model/ (868145)

61 exp Rodent/ (3009466)

62 (rat or rats or mouse or mice).ti. (1283287) 63 56 or 57 or 58 or 59 or 60 or 61 or 62 (6713559) 64 55 not 63 (347559)

65 44 and 64 (367) 66 44 not 65 (8592) Records Retrieved:

Systematic review = 367 Other study design = 8592

(6)

American Society of Hematology Guidelines for Management of Venous Thromboembolism: Diagnosis of Venous Thromboembolism

OVERVIEW

Interface: Cochrane Library

Database: Cochrane Database of Systematic Reviews Date of Search: May 9th, 2016

Study Types: Systematic reviews Limits: Publication date from 2006 Search Strategy: search terms (number of results) Any diagnostic intervention (CTPA, CUS, D-dimer, VQ):

#1 MeSH descriptor: [Ultrasonography] this term only 940

#2 MeSH descriptor: [Ultrasonography, Doppler] this term only 542

#3 (ultrasound* or ultrason* or sonograph*) 24608

#4 #1 or #2 or #3 24608

#5 MeSH descriptor: [Ventilation-Perfusion Ratio] explode all trees 132

#6 (lung near/1 (ventilation or perfusion)):ti,ab,kw 1068

#7 (lung near ventilation near scan):ti,ab,kw 19

#8 (lung near perfusion near scan):ti,ab,kw 42

#9 (lung near/1 scan):ti,ab,kw 66

#10 (VQ scan) 11

#11 #5 or #6 or #7 or #8 or #9 or #10 1218

#12 MeSH descriptor: [Fibrin Fibrinogen Degradation Products] this term only 488

#13 (D-dimer or d dimer) 1190

#14 (label* near/2 (fibrogen or fibrinogen)) 63

#15 #12 or #13 or #14 1400

#16 MeSH descriptor: [Tomography, X-Ray Computed] this term only 4171

#17 MeSH descriptor: [Cone-Beam Computed Tomography] explode all trees 139

#18 MeSH descriptor: [Tomography, Spiral Computed] this term only 215

#19 (compute* tomograph* or compute*-tomograph*) 13501

#20 (CT or CAT or CAPT):ti,ab 10276

#21 #16 or #17 or #18 or #19 or #20 18898

#22 #4 or #11 or #15 or 21 130946 VTE terms:

#23 MeSH descriptor: [Venous Thrombosis] explode all trees 2448

#24 MeSH descriptor: [Thromboembolism] explode all trees 1892

#25 MeSH descriptor: [Venous Thromboembolism] explode all trees 513

#26 MeSH descriptor: [Pulmonary Embolism] explode all trees 982

#27 MeSH descriptor: [Thrombophlebitis] this term only 1095

#28 (DVT or VTE or PE) 9108

#29 ((Pulmon* or vein or venous or lung) near (Emboli* or thromb*)) 9413

#30 (Thrombus* or thrombotic* or thrombolic* or thromboemboli* or thrombos* or embol*) 22668

#31 (((deep or thromb* or stasis) near/2 (vein* or venous)) or (blood flow stasis or blood clot)) 8726

#32 #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 30977

#33 #22 and #32 7717 Diagnosis filter:

#34 MeSH descriptor: [Sensitivity and Specificity] explode all trees 17846

(7)

American Society of Hematology Guidelines for Management of Venous Thromboembolism: Diagnosis of Venous Thromboembolism

#35 (sensitivity or specificity) 59020

#36 (predictive adj3 value$) 157

#37 MeSH descriptor: [Diagnostic Errors] explode all trees 2854

#38 (false adj positiv*) or (false adj negativ*) 202

#39 (observer adj variation*) 263

#40 (roc adj curve*) 43

#41 (likelihood adj3 ratio*) 638

#42 MeSH descriptor: [Likelihood Functions] explode all trees 393

#43 MeSH descriptor: [Thromboembolism] explode all trees and with qualifier(s): [Diagnosis - DI, Radiography - RA, Radionuclide imaging - RI, Ultrasonography - US] 229

#44 MeSH descriptor: [Thrombophlebitis] explode all trees and with qualifier(s): [Diagnosis - DI, Radiography - RA, Radionuclide imaging - RI, Ultrasonography - US] 260

#45 MeSH descriptor: [Venous Thrombosis] explode all trees and with qualifier(s): [Diagnosis - DI, Radiography - RA, Radionuclide imaging - RI, Ultrasonography - US] 537

#46 #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 67078

#47 #33 and #46 Publication Year from 2006 to 2016 1935 Annotation: Any diagnostic intervention AND VTE AND Diagnosis filter

All Results (1935) Cochrane Reviews (1443) Review (1206)

Protocol

Other Reviews (87) Trials (342)

Methods Studies (2) Technology Assessments (1) Economic Evaluations (48) Cochrane Groups (12) Records Retrieved: 1294

Cochrane reviews: 1206 Other reviews: 87

Technology Assessments: 1

(8)

Supplementary Material 2. Evidence profiles for intermediate-risk and high-risk patients with suspected pulmonary embolism

D-Dimer

Should DD be used to diagnose (20% Preval) PE in Patients?

Click here for interactive Summary of Findings (iSoFs).

Patient or population: Patients with suspicion of pulmonary embolism New test: D-Dimer

Setting: Inpatient and outpatient

Pooled sensitivity: 0.97 (95% CI: 0.96 to 0.98) | Pooled specificity: 0.41 (95% CI: 0.36 to 0.46)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 20%1,2 in patients suspected of

having PE without risk factors.

True positives 194 (192 to 196)

22849

(34) ⨁⨁⨁

MODERATEa,b

False negatives 6 (4 to 8)

True negatives 328 (288 to 368)

22849

(34) ⨁⨁⨁

MODERATEa,b

False positives 472 (432 to 512)

Inconclusive test results 0 22849

(34) -

Complications arising from the diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

(9)

b. Minor inconsistency for sensitivity noted but judged to be insufficient to downgrade the certainty of evidence. Certainty of evidence was downgraded for serious unexplained inconsistency in specificity, with range from 12.8% to 64%.

Should DD be used to diagnose (50% 75% Preval) PE in Patients?

Click here for interactive Summary of Findings (iSoFs).

Patient or population: Patients with suspicion of pulmonary embolism New test: D-Dimer

Setting: Inpatient and outpatient

Pooled sensitivity: 0.97 (95% CI: 0.96 to 0.98) | Pooled specificity: 0.41 (95% CI: 0.36 to 0.46)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 50%1,2 in patients

suspected of having PE without risk factors.

Prevalence 75%1,2 in patients suspected of having PE without risk

factors.

True positives 485 (480 to 490) 728 (720 to 735)

22849

(34) ⨁⨁⨁

MODERATEa,b

False negatives 15 (10 to 20) 22 (15 to 30)

True negatives 205 (180 to 230) 103 (90 to 115)

22849

(34) ⨁⨁⨁

MODERATEa,b

False positives 295 (270 to 320) 147 (135 to 160)

Inconclusive test results 0 22849

(34) -

Complications arising from the diagnostic test

Not reported CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

(10)

b. Minor inconsistency for sensitivity noted but judged to be insufficient to downgrade the certainty of evidence. Certainty of evidence was downgraded for serious unexplained inconsistency in specificity, with range from 12.8% to 64%.

Compression Ultrasound

Should CUS be used to diagnose (20% preval) PE in patients?

Click here for interactive Summary of Findings (iSoFs).

Patient or population: Patients with suspected pulmonary embolism New test: Proximal Compression Ultrasound

Setting: Inpatient and outpatient

Pooled sensitivity: 0.49 (95% CI: 0.31 to 0.66) | Pooled specificity : 0.96 (95% CI: 0.95 to 0.98)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 20%1,2 in patients suspected of

having PE without risk factors.

True positives 98 (62 to 132)

1715

(7) ⨁⨁◯◯

LOW a,b

False negatives 102 (68 to 138)

True negatives 768 (760 to 784)

1715

(7) ⨁⨁◯◯

LOW a,b

False positives 32 (16 to 40)

Inconclusive test results 0 1715

(7) -

Complications arising from the diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

(11)

b. Certainty of evidence was downgraded for serious unexplained inconsistency in sensitivity, with range from 18.4% to 96.7%. Minor inconsistency for specificity noted but judged to be insufficient to downgrade the certainty of evidence.

.

Should CUS be used to diagnose (50%, 75% preval) PE in patients?

Click here for interactive Summary of Findings (iSoFs).

Patient or population: Patients with suspected pulmonary embolism New test: Proximal Compression Ultrasound

Setting: Inpatient and outpatient

Pooled sensitivity : 0.49 (95% CI: 0.31 to 0.66) | Pooled specificity : 0.96 (95% CI: 0.95 to 0.98)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 50%1,2 in patients

suspected of having PE without risk factors.

Prevalence 75%1,2 in patients suspected of having PE without

risk factors.

True positives 245 (155 to 330) 368 (235 to 495)

1715

(7) ⨁⨁◯◯

LOW a,b

False negatives 255 (170 to 343) 382 (255 to 518)

True negatives 480 (475 to 490) 240 (238 to 245)

1715

(7) ⨁⨁◯◯

LOW a,b

False positives 20 (10 to 25) 10 (5 to 12)

Inconclusive test results 0 1715

(7) -

Complications arising from the diagnostic

test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

(12)

b. Certainty of evidence was downgraded for serious unexplained inconsistency in sensitivity, with range from 18.4% to 96.7%. Minor inconsistency for specificity noted but judged to be insufficient to downgrade the certainty of evidence.

CTPA

Should CTPA be used to diagnose (20% preval) PE in patients?

Click here for interactive Summary of Findings (iSoFs).

Patient or population: Patients with suspected pulmonary embolism New test: CTPA

Setting: Inpatient and outpatient

Pooled sensitivity: 0.94 (95% CI: 0.89 to 0.97) | Pooled specificity: 0.98 (95% CI: 0.97 to 0.99)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 20%1,2 in patients suspected of

having PE without risk factors.

True positives 188 (178 to 194)

4392

(16) ⨁⨁⨁

MODERATEa,b

False negatives 12 (6 to 22)

True negatives 784 (776 to 792)

4392

(16) ⨁⨁⨁

MODERATEa,b

False positives 16 (8 to 24)

Inconclusive test results 115 4392

(16) -

Complications arising from the diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

(13)

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

b. Certainty of evidence was downgraded for serious unexplained inconsistency in sensitivity, with range from 63% to 99.2%. Minor inconsistency for specificity noted but judged to be insufficient to downgrade the certainty of evidence.

Should CTPA be used to diagnose (50%, 75% preva)l PE in patients?

Click here for interactive Summary of Findings (iSoFs).

Patient or population: Patients with suspected pulmonary embolism New test: CTPA

Setting: Inpatient and outpatient

Pooled sensitivity: 0.94 (95% CI: 0.89 to 0.97) | Pooled specificity: 0.98 (95% CI: 0.97 to 0.99)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 50%1,2 in patients

suspected of having PE without risk factors.

Prevalence 75%1,2 in patients suspected of having PE without risk

factors.

True positives 470 (445 to 485) 705 (668 to 728)

4392

(16) ⨁⨁⨁

MODERATEa,b

False negatives 30 (15 to 55) 45 (22 to 82)

True negatives 490 (485 to 495) 245 (243 to 248)

4392

(16) ⨁⨁⨁

MODERATEa,b

False positives 10 (5 to 15) 5 (2 to 7)

Inconclusive test results 115 4392

(16) -

Complications arising from the diagnostic

test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

(14)

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

b. Certainty of evidence was downgraded for serious unexplained inconsistency in sensitivity, with range from 63% to 99.2%. Minor inconsistency for specificity noted but judged to be insufficient to downgrade the certainty of evidence.

VQ Scan

Should VQ1 be used to diagnose (20% preval) PE in patients?

Patient or population: Patients with suspected pulmonary embolism

New test: VQ scan with High probability scan as positive, Low/Intermediate/Normal scan as negative Setting: Inpatient and outpatient

Pooled sensitivity: 0.58 (95% CI: 0.50 to 0.66) | Pooled specificity: 0.98 (95% CI: 0.96 to 0.99)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 20%1,2 in patients suspected of

having PE without risk factors.

True positives 116 (99 to 131)

3994

(13) ⨁⨁⨁

MODERATEa,b

False negatives 84 (69 to 101)

True negatives 787 (771 to 794)

3994

(13) ⨁⨁⨁

MODERATEa,b

False positives 13 (6 to 29)

Inconclusive test results 1849 3994

(13) -

Complications arising from the diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

(15)

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

b. Certainty of evidence was downgraded for serious unexplained inconsistency in sensitivity, with range from 13.9% to 84.6%. Minor inconsistency for specificity noted but judged to be insufficient to downgrade the certainty of evidence.

Should VQ1 be used to diagnose (50% 75% preval) PE in patients?

Patient or population: Patients with suspected pulmonary embolism

New test: VQ scan with High probability scan as positive, Low/Intermediate/Normal scan as negative Setting: Inpatient and outpatient

Pooled sensitivity: 0.58 (95% CI: 0.50 to 0.66) | Pooled specificity: 0.98 (95% CI: 0.96 to 0.99)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 50%1,2 in patients

suspected of having PE without risk factors.

Prevalence 75%1,2 in patients suspected of having PE without

risk factors.

True positives 289 (248 to 329) 434 (372 to 493)

3994

(13) ⨁⨁⨁

MODERATEa,b

False negatives 211 (171 to 252) 316 (257 to 378)

True negatives 492 (482 to 497) 246 (241 to 248)

3994

(13) ⨁⨁⨁

MODERATEa,b

False positives 8 (3 to 18) 4 (2 to 9)

Inconclusive test results 1849 3994

(13) -

Complications arising from the diagnostic test Not reported

CI: Confidence interval

(16)

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

b. Certainty of evidence was downgraded for serious unexplained inconsistency in sensitivity, with range from 13.9% to 84.6%. Minor inconsistency for specificity noted but judged to be insufficient to downgrade the certainty of evidence.

Should VQ2 be used to diagnose 20% preval PE in patients?

Patient or population: Patients with suspected pulmonary embolism

New test: VQ scan with High/Intermediate/Low probability scan as positive, Normal scan as negative Setting: Inpatient and outpatient

Pooled sensitivity : 0.98 (95% CI: 0.95 to 0.99) | Pooled specificity : 0.36 (95% CI: 0.27 to 0.45)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 20%1,2 in patients suspected of

having PE without risk factors.

True positives 196 (191 to 198)

3994

(13) ⨁⨁⨁

MODERATEa,b

False negatives 4 (2 to 9)

True negatives 285 (214 to 363)

3994

(13) ⨁⨁⨁

MODERATEa,b

False positives 515 (437 to 586)

Inconclusive test results 1849 3994

(13) -

Complications arising from the diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

(17)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

b. Minor inconsistency for sensitivity noted but judged to be insufficient to downgrade the certainty of evidence. Certainty of evidence was downgraded for serious unexplained inconsistency in specificity, with range from 10.9% to 81.8%.

Should VQ2 be used to diagnose (50%, 75% preval) PE in patients?

Patient or population: Patients with suspected pulmonary embolism

New test: VQ scan with High/Intermediate/Low probability scan as positive, Normal scan as negative Setting: Inpatient and outpatient

Pooled sensitivity : 0.98 (95% CI: 0.95 to 0.99) | Pooled specificity : 0.36 (95% CI: 0.27 to 0.45)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 50%1,2 in patients

suspected of having PE without risk factors.

Prevalence 75%1,2 in patients suspected of having PE without risk

factors.

True positives 490 (477 to 496) 734 (716 to 743)

3994

(13) ⨁⨁⨁

MODERATEa,b

False negatives 10 (4 to 23) 16 (7 to 34)

True negatives 178 (134 to 227) 89 (67 to 114)

3994

(13) ⨁⨁⨁

MODERATEa,b

False positives 322 (273 to 366) 161 (136 to 183)

Inconclusive test results 1849 3994

(13) -

Complications arising from the

diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

(18)

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

b. Minor inconsistency for sensitivity noted but judged to be insufficient to downgrade the certainty of evidence. Certainty of evidence was downgraded for serious unexplained inconsistency in specificity, with range from 10.9% to 81.8%.

Should VQ3 be used to diagnose (20% preval) PE in patients?

Patient or population: Patients with suspected pulmonary embolism

New test: VQ scan with High probability scan as positive, Normal scan as negative Setting: Inpatient and outpatient

Pooled sensitivity : 0.96 (95% CI: 0.91 to 0.98) | Pooled specificity : 0.95 (95% CI: 0.89 to 0.98)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 20%1,2 in patients suspected of

having PE without risk factors.

True positives 192 (183 to 197)

1799

(13) ⨁⨁⨁⨁

HIGHa,b

False negatives 8 (3 to 17)

True negatives 762 (708 to 785)

1799

(13) ⨁⨁⨁⨁

HIGHa,b

False positives 38 (15 to 92)

Inconclusive test results 0 1799

(13) -

Complications arising from the diagnostic test

Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

(19)

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

b. Minor inconsistency for sensitivity noted but judged to be insufficient to downgrade the certainty of evidence. Minor inconsistency for specificity noted but judged to be insufficient to downgrade the certainty of evidence.

Should VQ3 be used to diagnose (50%, 75% preval) PE in patients?

Patient or population: Patients with suspected pulmonary embolism

New test: VQ scan with High probability scan as positive, Normal scan as negative Setting: Inpatient and outpatient

Pooled sensitivity : 0.96 (95% CI: 0.91 to 0.98) | Pooled specificity : 0.95 (95% CI: 0.89 to 0.98)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 50%1,2 in patients

suspected of having PE without risk factors.

Prevalence 75%1,2 in patients suspected of having PE without risk

factors.

True positives 481 (457 to 492) 722 (686 to 738)

1799

(13) ⨁⨁⨁⨁

HIGHa,b

False negatives 19 (8 to 43) 28 (12 to 64)

True negatives 476 (443 to 491) 238 (221 to 245)

1799

(13) ⨁⨁⨁⨁

HIGHa,b

False positives 24 (9 to 57) 12 (5 to 29)

Inconclusive test results 0 1799

(13) -

Complications arising from the

diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

(20)

Explanations

a. Certainty of evidence not downgraded for risk of bias, though few studies had a combination of reference standards that as judged to be acceptable by a panel of clinical experts.

b. Minor inconsistency for sensitivity noted but judged to be insufficient to downgrade the certainty of evidence. Minor inconsistency for specificity noted but judged to be insufficient to downgrade the certainty of evidence.

Should Age adjusted Ddimer be used to diagnose (20% preval) PE in patients?

Click here for interactive Summary of Findings (iSoFs).

Patient or population: Patients with suspected pulmonary embolism New test: Age-Adjusted D-dimer

Setting: Inpatient and outpatient

Pooled sensitivity: 0.99 (95% CI: 0.98 to 1.00) | Pooled specificity: 0.47 (95% CI: 0.45 to 0.49)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 20%1,2 in patients suspected of

having PE without risk factors.

True positives 198 (196 to 200)

2885

(1) ⨁⨁⨁⨁

HIGH a

False negatives 2 (0 to 4)

True negatives 376 (360 to 392)

2885

(1) ⨁⨁⨁⨁

HIGH a

False positives 424 (408 to 440)

Inconclusive test results 0 2885

(1) -

Complications arising from the diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

Explanations

a. Certainty of evidence not downgraded for imprecision given the large population size, though only one prospective age-adjusted D-dimer study was identified for analysis.

(21)

Should Age adjusted Ddimer be used to diagnose (50% 75% preval) PE in patients?

Click here for interactive Summary of Findings (iSoFs).

Patient or population: Patients with suspected pulmonary embolism New test: Age-Adjusted D-dimer

Setting: Inpatient and outpatient

Pooled sensitivity: 0.99 (95% CI: 0.98 to 1.00) | Pooled specificity: 0.47 (95% CI: 0.45 to 0.49)

Test result

Number of results per 1,000 patients tested (95% CI)

Number of participants

(studies) Certainty of the Evidence (GRADE) Prevalence 50%1,2 in patients

suspected of having PE without risk factors.

Prevalence 75%1,2 in patients suspected of having PE without risk

factors.

True positives 495 (490 to 500) 742 (735 to 750)

2885

(1) ⨁⨁⨁⨁

HIGH a

False negatives 5 (0 to 10) 8 (0 to 5)

True negatives 235 (225 to 245) 118 (113 to 123)

2885

(1) ⨁⨁⨁⨁

HIGH a

False positives 265 (255 to 275) 132 (127 to 137)

Inconclusive test results 0 2885

(1) -

Complications arising from the

diagnostic test Not reported

CI: Confidence interval

1Ceriani E et al. J Thromb Haemost 2010;8(5):957. Pooled prevalence of PE with low PTP in North American studies 6.5% (5% used in table); in European studies 11.5% (15% used in table)

2 Disease prevalence applies to the index test in each pathway. Prevalence applied to the accuracy of each subsequent test depends on the result of the previous test in the pathway.

(22)

Explanations

a. Certainty of evidence not downgraded for imprecision given the large population size, though only one prospective age-adjusted D-dimer study was identified for analysis.

(23)

Supplementary Material 3. List of excluded studies during full-text review

Reasons for Exclusions:

Ineligible study design (not RCT, prospective study, cohort study, case

control, cross sectional study) 68

Inappropriate population (not evaluating upper extremity DVT) 44

Ineligible intervention (not test of interest) 45

Inappropriate outcome (unable to calculate complete test accuracy) 140

Full text not available 19

Author Year Title

1. Anonymous 1971 Detection of venous thrombosis

2. M. L. C. Sussman, W. J. 1973 Pulmonary scanning in pulmonary embolism 3. R. H. F. Alexander, R.;

Pizzorno, J.; Conn, R. 1974 Thrombophlebitis and thromboembolism: results of a prospective study 4. L. O. A. J. Almer, M.; Lilja, B. 1974 New techniques in the diagnosis of acute pulmonary embolism

5. Tow, A. L. 1975 Comparison of lung scanning and pulmonary angiography in the detection and follow up of pulmonary embolism: the urokinase pulmonary embolism trial experience

6. V. V. Kakkar 1977 Diagnosis of deep vein thrombosis and pulmonary embolism 7. Mostbeck 1978 Ventilation-perfusion lung scanning for pulmonary embolism 8. C. D. R. Marini, G.; Palla, A.;

Susini, G.; Maltinti, G.;

Santolicandro, A.; Giuntini, C.

1978 Perfusion scintigraphy versus pulmonary arteriography in the diagnosis of pulmonary embolism

9. Biello, A. G.; McKnight, R. C.;

Siegel, B. A. 1979 Ventilation-perfusion studies in suspected pulmonary embolism 10. M. F. Ahmad, J. W.; Pur-

Shahriari, A. A.; George, E. A.;

Donati, R. M.

1979 Radionuclide venography and lung scanning: Concise communication

11. H. G. Creutzig, S.; Creutzig, A.;

Reilmann, H.; Hundeshagen, H.

1983 Frequencies of segmental perfusion and ventilation abnormalities in lung scintigraphy

(24)

12. H. Sors, D. Safran, M. Stern, P.

Reynaud, J. Bons and P. Even 1984 An analysis of the diagnostic methods for acute pulmonary embolism 13. J. M. B. Rosen, D. R.; Siegel, B.

A.; Seldin, D. W.; Alderson, P.

O.

1985 Kr-81m ventilation imaging: clinical utility in suspected pulmonary embolism

14. A. B. Elias, J. L.; Lecorff, G.;

Lagrange, G.; Benichou, M.;

Serradimigni, A.

1987 [Value and place of real-time ultrasonic diagnosis combined with continuous-wave Doppler in the diagnosis and follow-up of thromboembolic disease]

15. Hull, G. E.; Carter, C. J.;

Coates, G.; Gill, G. J.; Sackett, D. L.; Hirsh, J.; Thompson, M.

1988 Pulmonary embolism in outpatients with pleuritic chest pain

16. Vreim, H. A.; Alavai, A.;

Greenspan, R. H.; Hales, C. A.;

Stein, P. D.; Terrin, M.; Weg, J.

G.; Athanasoulis, C.;

Gottschalk, A.

1990 Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)

17. PIOPED Investigators 1990 Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)

18. J. C. v. S. de Valois, C. C.;

Verzijlbergen, F.; van

Ramshorst, B.; Eikelboom, B.

C.; Meuwissen, O. J.

1990 Contrast venography: from gold standard to 'golden backup' in clinically suspected deep vein thrombosis

19. D. M. P. Becker, J. T.;

Schoonover, F. W.; Teates, C.

D.

1990 Suspected pulmonary embolism and lung scan interpretation: trial of a Bayesian reporting method

20. E. D. M. Baldridge, M. A.;

Welling, R. E. 1990 Clinical significance of free-floating venous thrombi

21. Leitha, W.; Dudczak, R. 1991 Pulmonary embolism. Efficacy of D-dimer and thrombin-antithrombin III complex determinations as screening tests before lung scanning

22. Stein, R. E.; Gottschalk, A.;

Saltzman, H. A.; Terrin, M. L.;

Weg, J. G.

1991 Diagnostic utility of ventilation/perfusion lung scans in acute pulmonary embolism is not diminished by pre-existing cardiac or pulmonary disease

23. U. S. Kroschel, K.; Reuss, J.;

Rettenmaier, G. 1991 [Sonographic imaging of lung emboli. Results of a prospective study]

(25)

24. C. Szliska and B. Jeberger 1991 The D-Dimer test for the diagnosis of thrombo-embolism. [German]

25. Quinn, B. T.; Terrin, M. L.;

Thrall, J. H.; Athanasoulis, C.

A.; McKusick, K. A.; Stein, P.

D.; Hales, C. A.

1992 A prospective investigation of pulmonary embolism in women and men

26. B. A. L. Lesser, K. V., Jr.; Stein, P. D.; Saltzman, H. A.; Chen, J.;

Thompson, B. T.; Hales, C. A.;

Popovich, J., Jr.; Greenspan, R.

H.; Weg, J. G.

1992 The diagnosis of acute pulmonary embolism in patients with chronic obstructive pulmonary disease

27. C. G. Demers, J. S.; Johnston,

M.; Brill-Edwards, P.; Panju, A. 1992 D-dimer and thrombin-antithrombin III complexes in patients with clinically suspected pulmonary embolism

28. H. Bounameaux 1992 [Significance of the determination of D-dimers in venous thrombo-embolic disease]

29. Ginsberg, P. A.; Demers, C.;

Donovan, D.; Panju, A. 1993 D-dimer in patients with clinically suspected pulmonary embolism 30. Goldhaber, G. R.; Elliott, C. G.;

Haire, W. D.; Toltzis, R.;

Blacklow, S. C.; Doolittle, M.

H.; Weinberg, D. S.

1993 Quantitative plasma D-dimer levels among patients undergoing pulmonary angiography for suspected pulmonary embolism

31. Pappas, G.; Harrison, K.;

Purnell, G.; Canton, M.;

Palmer, S.; Fink, L. M.

1993 The application of a rapid D-dimer test in suspected pulmonary embolus

32. E. J. v. d. E. van Beek, B.;

Berckmans, R. J.; van der Heide, Y. T.; Brandjes, D. P.;

Sturk, A.; ten Cate, J. W.

1993 A comparative analysis of D-dimer assays in patients with clinically suspected pulmonary embolism

33. P. D. H. Stein, R. D.; Saltzman,

H. A.; Pineo, G. 1993 Strategy for diagnosis of patients with suspected acute pulmonary embolism 34. P. D. G. Stein, A.; Henry, J. W.;

Shivkumar, K. 1993 Stratification of patients according to prior cardiopulmonary disease and probability assessment based on the number of mismatched segmental equivalent perfusion defects.

Approaches to strengthen the diagnostic value of ventilation/perfusion lung scans in acute pulmonary embolism

35. P. D. H. Stein, J. W.;

Gottschalk, A. 1993 Mismatched vascular defects. An easy alternative to mismatched segmental equivalent defects for the interpretation of ventilation/perfusion lung scans in pulmonary embolism

(26)

36. R. P. D. Beecham, G. S.;

Cronan, J. J.; Spearman, M. P.;

Murphy, T. P.; Scola, F. H.

1993 Is bilateral lower extremity compression sonography useful and cost-effective in the evaluation of suspected pulmonary embolism?

37. Lenzhofer, F.; Haydl, H.;

Kardeis, J.; Gruber, G.;

Ganzinger, U.; Schuster, R.;

Nowak-Sattelberger, R.

1993 Prospective study of determining the value of D-dimer in diagnosing pulmonary embolism

38. Perrier, H.; Morabia, A.; de Moerloose, P.; Slosman, D.;

Unger, P. F.; Junod, A.

1994 Contribution of D-dimer plasma measurement and lower-limb venous ultrasound to the diagnosis of pulmonary embolism: a decision analysis model

39. Quinn, R.; Butler, S. P.; Glenn, D. W.; Travers, P. L.; Wellings, G.; Kwan, Y. L.

1994 Pulmonary embolism in patients with intermediate probability lung scans: diagnosis with Doppler venous US and D-dimer measurement

40. Sostman, R. E. Coleman, D. M.

DeLong, G. E. Newman and S.

Paine

1994 Evaluation of revised criteria for ventilation-perfusion scintigraphy in patients with suspected pulmonary embolism

41. Allescia, G.; Formichi, B.;

Giuntini, C.; Marini, C.;

Miniati, M.; Pistolesi, M.;

Prediletto, R.; Sostman, H. D.

1994 Invasive and noninvasive diagnosis of pulmonary embolism: Preliminary results of the Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis (PISA-PED)

42. P. D. H. Stein, R. D.; Pineo, G. 1995 Strategy that includes serial noninvasive leg tests for diagnosis of thromboembolic disease in patients with suspected acute pulmonary embolism based on data from PIOPED. Prospective Investigation of Pulmonary Embolism Diagnosis

43. J. L. Rochemaure, J. P.; Achkar,

A.; Fretault, J.; Samama, M. 1995 Value of the determination of D-dimers in the diagnostic approach of venous thrombo-embolic disorders. [French]

44. J. L. B. Bosson, P. D.; Chirpaz, E.; Carpentier, P. H.; Vuillez, J.

P.

1995 [Pulmonary scintigraphy in the diagnosis of pulmonary embolism]

45. M. P. W. Rosen, J.; Donohoe, K.; Porter, D. H.; Kim, D.;

McArdle, C.

1995 Role of lower extremity US in patients with clinically suspected pulmonary embolism

46. E. J. Stern 1995 Is helical CT more accurate or more sensitive at finding clots than the radionuclide study?

47. Eze, A. J.; Kerr, R. P.; Harada,

R. N.; Domeracki, F. 1996 Is venous duplex imaging an appropriate initial screening test for patients with suspected pulmonary embolism?

Références

Documents relatifs

only one study would be added in the systematic review but not included in the meta-analysis. patients hospitalized in psychiatry settings, or 131.. subjects with

Hence, we aimed to assess the association between the clinical presentation of VTE (PE or DVT) and the risk of 3-month adverse outcomes (i.e. PE, major bleeding and death during

The levels of all biomarkers studied were found to be higher in HF patients compared to controls, except for salivary amylase that was found to be decreased in HF patients in one

CI: Confidence interval; CRP: C-reactive protein; FN: False negative; FP: False positive; HCA: Histological chorioamnionitis; HCA/Funisitis: Histologic chorioamnionitis

Methods: We systematically searched for peer-reviewed evidence on the risk of VTE in patients with COVID-19, in PubMed, Embase and Twitter, and for guidelines or guidance documents

For patients discharged without treatment due to negative diagnostic test results, there were no outcomes reported by a published systematic review, VTE treatment guideline, or

Study Types: Systematic reviews; diagnostic test accuracy studies; randomized trials. Limits:

Data extracted included general study characteristics (authors, publication year, country, study design), diagnostic index test and reference standard, prevalence of lower